Gavi says new tuberculosis (TB) vaccines could prevent up to 7.3 million deaths between 2030 and 2050. The estimate is linked to the potential rollout of more effective vaccines and expanded protection in high-burden settings.
Outlets report the figures similarly but emphasize different implications. The Citizen frames the prospect as both a public-health and economic opportunity, noting that vaccine development and deployment could bring broader financial benefits. IOL focuses more on the scale of lives saved and underscores Gavi’s view that results depend on achieving affordable, reliable vaccine supply for countries with the highest TB burdens.
Together, the reports present a common outlook: if new TB vaccines are made available and delivered effectively, they could substantially reduce TB mortality over the coming decades, though execution factors such as access and supply are critical.
